HK1200467A1 - Anti-c5a antibodies and methods for using the antibodies -c5a - Google Patents

Anti-c5a antibodies and methods for using the antibodies -c5a

Info

Publication number
HK1200467A1
HK1200467A1 HK15100911.9A HK15100911A HK1200467A1 HK 1200467 A1 HK1200467 A1 HK 1200467A1 HK 15100911 A HK15100911 A HK 15100911A HK 1200467 A1 HK1200467 A1 HK 1200467A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
methods
Prior art date
Application number
HK15100911.9A
Other languages
English (en)
Chinese (zh)
Inventor
Yuchun Zhang
Russell P Rother
Paul P Tamburini
Douglas L Sheridan
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of HK1200467A1 publication Critical patent/HK1200467A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
HK15100911.9A 2010-04-30 2013-04-19 Anti-c5a antibodies and methods for using the antibodies -c5a HK1200467A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33026010P 2010-04-30 2010-04-30
US201161471465P 2011-04-04 2011-04-04

Publications (1)

Publication Number Publication Date
HK1200467A1 true HK1200467A1 (en) 2015-08-07

Family

ID=44861943

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13104789.2A HK1177752A1 (en) 2010-04-30 2013-04-19 Anti-c5a antibodies and methods for using the antibodies -c5a
HK15100911.9A HK1200467A1 (en) 2010-04-30 2013-04-19 Anti-c5a antibodies and methods for using the antibodies -c5a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13104789.2A HK1177752A1 (en) 2010-04-30 2013-04-19 Anti-c5a antibodies and methods for using the antibodies -c5a

Country Status (22)

Country Link
US (10) US9011852B2 (pt)
EP (2) EP2563813B1 (pt)
JP (3) JP6022441B2 (pt)
KR (1) KR101800913B1 (pt)
CN (2) CN103201289B (pt)
AU (1) AU2011245117B2 (pt)
BR (1) BR112012027900A2 (pt)
CA (1) CA2797856C (pt)
CO (1) CO6660465A2 (pt)
DK (1) DK2563813T3 (pt)
EA (1) EA028899B1 (pt)
ES (2) ES2623799T3 (pt)
HK (2) HK1177752A1 (pt)
HR (1) HRP20151213T1 (pt)
IL (2) IL222688A (pt)
MX (1) MX340696B (pt)
NZ (2) NZ603226A (pt)
PL (1) PL2563813T3 (pt)
PT (1) PT2563813E (pt)
SG (1) SG185383A1 (pt)
SI (1) SI2563813T1 (pt)
WO (1) WO2011137395A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
DK2563813T3 (en) 2010-04-30 2015-11-30 Alexion Pharma Inc Anti-c5a antibodies and methods of use of antibodies
EP2468295A1 (en) * 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
US11067586B2 (en) * 2011-11-16 2021-07-20 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
PL2817329T3 (pl) 2012-02-20 2019-07-31 Swedish Orphan Biovitrum Ab (Publ) Polipeptydy wiążące z c5 ludzkiego dopełniacza
CN110818798A (zh) 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
AU2013337638B2 (en) 2012-11-02 2018-10-25 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3290922A1 (en) * 2013-08-07 2018-03-07 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
SG11201607740TA (en) 2014-03-20 2016-10-28 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
EP3274468B1 (en) 2015-03-25 2019-02-20 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
US20180074077A1 (en) 2015-03-25 2018-03-15 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
WO2016164358A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
US11203634B2 (en) 2015-10-07 2021-12-21 Alexion Pharmaceuticals, Inc. Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
JP7221691B2 (ja) * 2015-10-30 2023-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｔ細胞媒介性同種移植片血管障害の増悪を抑制する方法
CN110698558B (zh) * 2015-12-24 2021-09-10 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
CN109328197A (zh) * 2016-06-07 2019-02-12 诺华股份有限公司 用于治疗具有补体c5多态性的患者的抗c5抗体
CN116751293A (zh) 2016-06-14 2023-09-15 瑞泽恩制药公司 抗c5抗体及其用途
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
EP3529619B1 (en) 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5a in a sample
US11965884B2 (en) 2016-10-19 2024-04-23 Alexion Pharmaceuticals, Inc. Method of quantitating unbound C5 in a sample
WO2018081400A1 (en) 2016-10-27 2018-05-03 Alexion Pharmaceuticals Inc. Assay for c5b-9 deposition in complement-associated disorders
WO2018165062A1 (en) * 2017-03-06 2018-09-13 The Trustees Of The University Of Pensylvania Anti-c5 antibodies and uses thereof
AU2018237300A1 (en) * 2017-03-23 2019-10-17 The Trustees Of The University Of Pennsylvania Anti-C5a antibodies and uses thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP3658184B1 (en) 2017-07-27 2023-09-06 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
EP3724226A1 (en) * 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
JP2021523101A (ja) * 2018-05-08 2021-09-02 アムジエン・インコーポレーテツド 切断可能なｃ末端電荷対タグを有する二重特異性抗体
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
JP7193628B2 (ja) * 2018-07-06 2022-12-20 北京天成新脉生物技▲術▼有限公司 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用
CA3115545A1 (en) 2018-11-13 2020-05-22 Jn Biosciences Llc Bispecific antibodies for activation of immune cells
AU2020235263A1 (en) * 2019-03-14 2021-09-02 Morphosys Ag Antibodies targeting C5aR
AU2020401102A1 (en) * 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Anti-C5 antibody for the treatment of neuromyelitis optica spectrum disorder
US20230068783A1 (en) * 2020-01-21 2023-03-02 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling
CA3165703A1 (en) * 2020-01-23 2021-07-29 Junling LIU Related target for treating fibrotic diseases and applications thereof
CN116406287A (zh) 2020-04-16 2023-07-07 巴黎公共医疗救助机构 治疗由病毒引起的补体介导的障碍的方法
JP2023532316A (ja) * 2020-06-24 2023-07-27 スタイドソン・（ベイジン）・バイオファーマシューティカルズ・カンパニー・リミテッド Ｃ５ａを特異的に認識する抗体およびその使用
JP6960508B1 (ja) * 2020-07-29 2021-11-05 シスメックス株式会社 試料中のウイルス抗原を測定する方法、抗体セット及び試薬キット
WO2022072495A2 (en) * 2020-10-01 2022-04-07 Academia Sinica Potent neutralizing antibodies for prevention and treatment of covid-19
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof
WO2023116574A1 (zh) * 2021-12-22 2023-06-29 舒泰神（北京）生物制药股份有限公司 一种分离的抗C5a抗体及其制剂与应用
CN114747535B (zh) * 2022-03-29 2024-03-22 华南理工大学 一种急性脓毒症非人灵长类动物模型及其构建方法
WO2023186054A1 (zh) * 2022-04-02 2023-10-05 舒泰神（北京）生物制药股份有限公司 特异性识别c5a的抗体及其应用
CN116925229B (zh) * 2023-09-19 2023-12-15 南京驯鹿生物技术股份有限公司 一种靶向gprc5d的抗体及其应用
CN117447602B (zh) * 2023-12-22 2024-03-19 北京索莱宝科技有限公司 猪IgM的抗体及其应用

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ES2054667T3 (es) * 1986-04-28 1994-08-16 Cetus Oncology Corp Anticuerpos monoclonales contra c5a y des-arg74-c5a, su produccion y uso.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US20040010810A1 (en) 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU659824B2 (en) 1990-10-31 1995-06-01 Cell Genesys, Inc. Retroviral vectors useful for gene therapy
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
GB9026191D0 (en) 1990-12-01 1991-01-16 Harris Pharma Ltd Breath actuated dispensing device
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2135313A1 (en) 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US5346196A (en) 1993-03-05 1994-09-13 U.S. News & World Report, L.P. Cycle binding line with signature replacement indicator means
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5837499A (en) 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
US5807824A (en) 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
CZ295827B6 (cs) 1994-03-07 2005-11-16 Nektar Therapeutics Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20050287630A1 (en) 1995-04-27 2005-12-29 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9626960D0 (en) 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
WO2000061178A1 (en) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
JP2002541213A (ja) 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
GB9910975D0 (en) 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6394314B1 (en) 1999-10-12 2002-05-28 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU7141701A (en) 2000-08-30 2002-03-13 Univ Johns Hopkins Devices for intraocular drug delivery
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
WO2002098920A1 (en) 2001-06-01 2002-12-12 Biogen, Inc. Molecules and methods for inhibiting shedding of kim-1
EP3372243A1 (en) * 2001-08-17 2018-09-12 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
EP2287198A3 (en) 2002-03-13 2011-05-25 Biogen Idec MA Inc. Anti-alpha V beta 6 antibodies
JP4290564B2 (ja) 2002-03-19 2009-07-08 チルドレンズ ホスピタル メディカル センター Ｃ５ａアナフィラトキシンの突然変異タンパク質、このような突然変異タンパク質をコードする核酸分子ならびにＣ５ａアナフィラトキシンの突然変異タンパク質の医薬的使用
SE523691C2 (sv) 2002-07-02 2004-05-11 Parker Hannifin Ab Manöverbox för manövrering av ett kraftdon
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
AU2003301813A1 (en) 2002-10-30 2004-06-07 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
AU2003290605A1 (en) 2002-11-05 2004-06-03 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
US20060167435A1 (en) 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
CN1750844B (zh) 2003-02-21 2010-09-08 健泰科生物技术公司 凝集素途径特异性补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途
EP1628530B8 (en) * 2003-05-15 2012-08-01 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
CA2527726A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
CA2534077A1 (en) 2003-07-29 2005-02-10 Morphotek Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0416328D0 (en) 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
EP1817340B1 (en) 2004-11-12 2012-05-16 Xencor, Inc. Fc variants with altered binding to fcrn
WO2007094754A2 (en) 2005-01-27 2007-08-23 The Regents Of The University Of Califordnia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2618482C (en) 2005-08-19 2014-10-07 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
CA2624393C (en) 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US8037880B2 (en) 2006-04-07 2011-10-18 The University Of Western Ontario Dry powder inhaler
AU2007276707A1 (en) 2006-07-21 2008-01-24 Promics Pty Ltd Treatment for intimal hyperplasia and related conditions
RU2009110154A (ru) 2006-08-22 2010-09-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
WO2008048689A2 (en) 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
JP5374360B2 (ja) 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
US20090110679A1 (en) 2007-07-13 2009-04-30 Luk-Chiu Li Methods and compositions for pulmonary administration of a TNFa inhibitor
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2009015087A2 (en) 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
MX2010006097A (es) * 2007-12-05 2010-08-04 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para tratar el prurito.
AU2009215846B2 (en) 2008-02-19 2014-08-14 The Trustees Of The University Of Pennsylvania Complement inhibitors as therapeutic agents for treatment of cancer
US8940299B2 (en) 2008-02-28 2015-01-27 Case Western Reserve University Method of treating cancer
US20110182910A1 (en) 2008-03-06 2011-07-28 Medof M Edward Method of treating t cell mediated disorders
US20090324585A1 (en) 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
CA2728909A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
CN109045296A (zh) 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
DK2563813T3 (en) 2010-04-30 2015-11-30 Alexion Pharma Inc Anti-c5a antibodies and methods of use of antibodies
EA201291133A1 (ru) 2010-04-30 2013-04-30 Алексион Фармасьютикалз, Инк. Антитела, обладающие пониженной иммуногенностью в организме человека
WO2014066307A1 (en) 2012-10-23 2014-05-01 The Procter & Gamble Company Methods for transferring discrete articles onto a web

Also Published As

Publication number Publication date
JP6022441B2 (ja) 2016-11-09
SG185383A1 (en) 2012-12-28
EP2563813A1 (en) 2013-03-06
US20160053004A1 (en) 2016-02-25
CA2797856A1 (en) 2011-11-03
US20160159892A1 (en) 2016-06-09
NZ629829A (en) 2015-11-27
HK1177752A1 (en) 2013-08-30
US20230159627A1 (en) 2023-05-25
WO2011137395A1 (en) 2011-11-03
US20150183859A1 (en) 2015-07-02
SI2563813T1 (sl) 2015-12-31
US20160207997A1 (en) 2016-07-21
ES2552954T3 (es) 2015-12-03
EP2824111B1 (en) 2017-03-22
CN105963694B (zh) 2019-11-05
CO6660465A2 (es) 2013-04-30
US20160376357A1 (en) 2016-12-29
JP2016117771A (ja) 2016-06-30
US9434784B1 (en) 2016-09-06
US9221901B2 (en) 2015-12-29
US10450370B2 (en) 2019-10-22
KR101800913B1 (ko) 2017-12-20
JP2013526861A (ja) 2013-06-27
IL240898A (en) 2017-09-28
MX2012012686A (es) 2013-02-26
CN103201289B (zh) 2016-06-08
KR20130062287A (ko) 2013-06-12
CA2797856C (en) 2018-09-18
BR112012027900A2 (pt) 2020-05-12
AU2011245117A1 (en) 2012-11-22
US9371378B1 (en) 2016-06-21
EP2824111A3 (en) 2015-04-29
US11407821B2 (en) 2022-08-09
EA028899B1 (ru) 2018-01-31
HRP20151213T1 (hr) 2016-01-01
US20200207842A1 (en) 2020-07-02
US9309310B2 (en) 2016-04-12
IL222688A (en) 2015-09-24
US20160264654A1 (en) 2016-09-15
US9469690B2 (en) 2016-10-18
EA201291147A1 (ru) 2013-08-30
PL2563813T3 (pl) 2016-01-29
CN103201289A (zh) 2013-07-10
IL240898A0 (en) 2015-10-29
NZ603226A (en) 2015-02-27
US20180273612A1 (en) 2018-09-27
AU2011245117B2 (en) 2015-03-12
PT2563813E (pt) 2015-11-26
DK2563813T3 (en) 2015-11-30
CN105963694A (zh) 2016-09-28
EP2563813B1 (en) 2015-08-26
US9011852B2 (en) 2015-04-21
EP2824111A2 (en) 2015-01-14
IL222688A0 (en) 2012-12-31
MX340696B (es) 2016-07-21
US9963503B2 (en) 2018-05-08
ES2623799T3 (es) 2017-07-12
EP2563813A4 (en) 2013-10-02
US20130224187A1 (en) 2013-08-29
JP2016020367A (ja) 2016-02-04

Similar Documents

Publication Publication Date Title
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
IL240898A0 (en) Antibodies against a5c and methods of using the antibodies
IL288203B (en) Meditops and Meditop binding antibodies and their use
IL287270A (en) Anti-psgl-1 antibodies and their use
IL244197A0 (en) Antibodies against cd100 and methods of using them
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2611832A4 (en) ANTI-CXCL13 ANTIBODIES AND METHOD FOR THEIR USE
HK1179981A1 (zh) 的抗體及其用途
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof -15
ZA201206055B (en) Antibodies against cxcr4
EP2632952A4 (en) ANTI-SOD1 ANTIBODIES AND USES THEREOF
EP2785738A4 (en) ANTI-NPY ANTI-PYY ANTIBODIES AND USES THEREOF
EP2771351A4 (en) PAT-LM1 EPITOPES AND METHODS OF USE
EP2545378A4 (en) ANTI-LG3 ANTIBODIES AND USES THEREOF

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210501